Advertisement
Screener

IRONWOOD PHARMACEUTICALS, INC. (IRWD) Number of Reportable Segments

2.8 / 5 stars · 68/120 Roast Me

IRONWOOD PHARMACEUTICALS, INC. Number of Reportable Segments

IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Number of Reportable Segments of 1 segment for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Notes

us-gaap:NumberOfReportableSegments · last filed 2026-08-06

  • IRONWOOD PHARMACEUTICALS, INC. number of reportable segments for the quarter ending 2026-06-30 was 1.00 segment, a 0.00% change year-over-year.
  • IRONWOOD PHARMACEUTICALS, INC. number of reportable segments for the quarter ending 2026-03-31 was 1.00 segment, a 0.00% change year-over-year.
  • IRONWOOD PHARMACEUTICALS, INC. number of reportable segments for the quarter ending 2025-09-30 was 1.00 segment, a 0.00% change year-over-year.
  • IRONWOOD PHARMACEUTICALS, INC. number of reportable segments for the quarter ending 2025-06-30 was 1.00 segment, a 0.00% change year-over-year.
  • IRONWOOD PHARMACEUTICALS, INC. number of reportable segments for fiscal 2025 was 1.00 segment, a 0.00% change from fiscal 2024.
  • IRONWOOD PHARMACEUTICALS, INC. number of reportable segments for fiscal 2024 was 1.00 segment, a 0.00% change from fiscal 2023.
  • IRONWOOD PHARMACEUTICALS, INC. number of reportable segments for fiscal 2023 was 1.00 segment, a 0.00% change from fiscal 2022.
  • IRONWOOD PHARMACEUTICALS, INC. number of reportable segments for fiscal 2022 was 1.00 segment, a 0.00% change from fiscal 2021.
Period endNumber of Reportable Segments 0 monthNumber of Reportable Segments 3 monthNumber of Reportable Segments 6 monthNumber of Reportable Segments 9 monthNumber of Reportable Segments 12 month
2026-06-301.00 segment
10-Q · filed 2026-08-06
1.00 segment
10-Q · filed 2026-08-06
2026-03-311.00 segment
10-Q · filed 2026-05-07
2025-12-311.00 segment
10-K · filed 2026-02-26
2025-09-301.00 segment
10-Q · filed 2025-11-10
1.00 segment
10-Q · filed 2025-11-10
2025-06-301.00 segment
10-Q · filed 2026-08-06
1.00 segment
10-Q · filed 2026-08-06
2025-03-311.00 segment
10-Q · filed 2026-05-07
2024-12-311.00 segment
10-K · filed 2026-02-26
2024-09-301.00 segment
10-Q · filed 2025-11-10
1.00 segment
10-Q · filed 2025-11-10
2024-06-301.00 segment
10-Q · filed 2025-08-11
1.00 segment
10-Q · filed 2025-08-11
2024-03-311.00 segment
10-Q · filed 2025-05-12
2023-12-311.00 segment
10-K · filed 2025-03-31
2022-12-311.00 segment
10-K · filed 2025-03-31
2021-12-311.00 segment
10-K · filed 2024-02-16
2020-12-311.00 segment
10-K · filed 2023-02-16
2020-09-301.00 segment
10-Q · filed 2020-11-05
1.00 segment
10-Q · filed 2020-11-05
2020-06-301.00 segment
10-Q · filed 2020-08-06
1.00 segment
10-Q · filed 2020-08-06
2019-12-311.00 segment
10-K · filed 2022-02-18
2019-09-301.00 segment
10-Q · filed 2020-11-05
1.00 segment
10-Q · filed 2020-11-05
2019-06-301.00 segment
10-Q · filed 2020-08-06
1.00 segment
10-Q · filed 2020-08-06
2018-12-311.00 segment
10-K · filed 2021-02-17
2018-09-301.00 segment
10-Q · filed 2019-10-31
1.00 segment
10-Q · filed 2019-10-31
2018-06-301.00 segment
10-Q · filed 2019-07-30
1.00 segment
10-Q · filed 2019-07-30
2017-12-311.00 segment
10-K · filed 2018-02-22
2016-12-311.00 segment
10-K · filed 2017-02-22
2015-12-311.00 segment
10-K · filed 2016-02-19
2014-12-311.00 segment
10-K · filed 2015-02-18
2013-12-311.00 segment
10-K · filed 2014-02-07
2012-12-311.00 segment
10-K · filed 2013-02-21
2012-09-301.00 segment
10-Q · filed 2012-11-06
2010-09-212.00 segment
10-K · filed 2013-02-21

Similar stocks

Stock NameCountryMarket CapPE Ratio
Nuvectis Pharma, Inc. (NVCT)United States$0.705B-17.53
Climb Bio, Inc. (CLYM)United States$0.683B-13.03
Verastem, Inc. (VSTM)United States$0.706B-1.71
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
COLLEGIUM PHARMACEUTICAL, INC (COLL)United States$0.737B24.57
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
Faeth Therapeutics, Inc. (FTH)United States$0.750B
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
Neurogene Inc. (NGNE)$0.625B-4.46
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78